Its over-expression triggered proliferation and anchorage-independent growth in cells and acted as an oncomiR in breast cancer initiation through associating with cyclin D1 and c-Myc and downregulating SOX7, a tumor suppressor and a downstream target of miR-492. This evidence concerns the gene MYC and breast cancer.